US medical devices industry saw a drop of 26.61% in overall deal activity during April 2022, when compared with the last 12-month average, led by ArchiMed’s $1.2bn private equity deal with Natus Medical, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 80 deals worth $2.8bn were announced in April 2022, compared with the 12-month average of 109 deals.
venture financing was the leading category in the month in terms of volume with 61 deals, which accounted for 76.3% of all deals.
In second place was M&A with 16 deals, followed by private equity with three transactions, respectively accounting for 20% and 3.8% of overall deal activity in the US technology industry during the month.
In terms of value of deals, venture financing was the leading deal category in the US medical devices industry with total deals worth $1.24bn, while private equity and M&A deals totalled $1.2bn and $334.7m respectively.
US medical devices industry deals in April 2022: Top deals
The top five medical devices industry deals accounted for 73.6% of the overall value during April 2022.
The combined value of the top five medical devices deals stood at $2.04bn, against the overall value of $2.8bn recorded for the month.
The top five medical devices industry deals of April 2022 tracked by GlobalData were:
1) ArchiMed $1.2bn private equity deal with Natus Medical
2) The $300m venture financing of Biofourmis by CVS Health,Export Development Bank of Iran,General Atlantic,Mass Mutual Ventures,Openspace Ventures,Sequoia Capital and SoftBank Vision Fund II
3) Adams Street Partners,Altimeter Capital Management,Battery Ventures,Coatue,Dragoneer Investment Group and ICONIQ Growth $220m venture financing deal with Reify Health
4) The $170m acquisition of Inform Diagnostics by Fulgent Genetics
5) Impact Investment Partners,Japan Industrial Partners and NEC $150m venture financing deal with BostonGene
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.